证券代码：002038 证券简称：双鹭药业 公告编号：2024-037 北京双鹭药业股份有限公司 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、 董事会会议召开情况 北京双鹭药业股份有限公司（以下简称"公司"）第九届董事会第五次会议于 2024 年 11 月 21 日以现场结合通讯方式在公司总部会议室（北京海淀区碧桐园一号楼四层）召开，会议通 知于 2024 年 11 月 18 日以通讯方式送达。本次会议由董事长徐明波先生主持，会议应出席董事 6 名，实际出席董事 6 名，公司全体监事及高级管理人员列席了本次会议。本次会议的召集、 召开符合《公司法》、《公司章程》和《董事会议事规则》的有关规定。 二、 董事会会议审议情况 会议以投票表决方式，审议了以下议案： （一） 审议通过了《关于续聘大华会计师事务所（特殊合伙）为公司 2024 年度审计机 构的议案》 在 2023 年度审计过程中，大华严格按照既定的时间安排和工作计划实施对公司的年度审 计，并在约定时限内完成了所有审计程序，取得了充分适当的审计证据。大华审计成员也具有 ...

证券代码：002038 证券简称：双鹭药业 公告编号：2024-035 北京双鹭药业股份有限公司 拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 北京双鹭药业股份有限公司（以下简称"公司"或"本公司"）此次续聘大华会计师事 务所（特殊普通合伙）符合财政部、国务院国资委、证监会印发的《国有企业、上市公司 选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 本公司于 2024 年 11 月 21 日召开的第九届董事会第五次会议和第九届监事会第五次会 议审议通过了《关于续聘大华会计师事务所（特殊普通合伙）为公司 2024 年度审计机构的 议案》，拟续聘大华会计师事务所（特殊普通合伙）为公司 2024 年度会计师事务所。该议 案尚需提交公司 2024 年第一次临时股东大会审议，现将相关事项公告如下： （1）机构名称：大华会计师事务所（特殊普通合伙） （2）成立日期：2012 年 2 月 9 日成立（由大华会计师事务所有限公司转制为特殊普通 合伙企业） （3）组织形式：特殊普通合伙 （4）注册地址：北京市海淀区西四环中路 ...

证券代码：002038 证券简称：双鹭药业 公告编号：2024-036 一、董事辞职情况 北京双鹭药业股份有限公司（以下简称"公司"）董事会于 2024 年 11 月 19 日收到公司 董事王文新先生的辞职报告，王文新先生因工作调整（调任新乡国有资本运营集团有限公 司），申请辞去公司董事及相关专业委员会职务。王文新先生辞职后不再担任公司其他任何 职务，且未在公司及子公司任职。截止本公告日，王文新先生未持有公司股份。由于王文新 先生的辞职将导致公司第九届董事会成员人数低于公司章程规定人数，在公司股东大会补选 新任董事前，王文新先生将按照《公司法》、《证券法》等相关法律法规和《公司章程》的规 定，继续履行公司董事的相关职责。 王文新先生在担任公司董事期间勤勉尽责，公司对其任职期间为公司发展所做的贡献表 示衷心感谢。 二、补选董事情况 2024 年 11 月 21 日，公司召开第九届董事会第五次会议审议通过了《关于提名公司董 事候选人的议案》，经控股股东新乡白鹭投资集团有限公司推荐，董事会提名委员会审查通 过，董事会提名张家启先生（简历详见附件）为公司第九届董事会非独立董事候选人，同时 选举张家启先生担任第九届董事 ...

Financial Performance - The company's revenue and profit showed significant fluctuations in the first three quarters of 2024, primarily due to large fair value changes in financial assets and a high base from the previous year due to the flu outbreak [1][2] - The overall income and profit trends for the first three quarters are declining, and this trend is expected to continue throughout the year [2] - The company anticipates an improvement in performance next year, as most of the products participating in national procurement are newly launched and should not be negatively impacted by significant price drops [2] Product Development and Pipeline - The company has received approval for four new chemical drugs and has three drugs that have passed consistency evaluations [1] - New products in the health sector, including popular anti-aging products like alpha-lipoic acid and probiotics, are expected to be launched by the end of the year [2][3] - The company has submitted applications for several products, including recombinant human follicle-stimulating hormone injection and dasatinib tablets, with hopes that these will offset the impact of price reductions from procurement [4] Market Strategy and Response to Price Cuts - The company is implementing multiple strategies to mitigate the negative impacts of price cuts from procurement, including developing new potential products and reducing reliance on hospital sales by increasing the proportion of oral products [3] - The company has successfully opened stable e-commerce sales channels, enhancing its marketing strategies [3] - Future products entering procurement are expected to have a smaller market share, and the company plans to adopt a strategy of gaining market share through pricing [2][3] Investment and Partnerships - The company has invested in several firms, including Shouyao Holdings and Xinghao Pharmaceutical, and plans to hold these investments long-term due to their promising development [3] - The company maintains a value investment philosophy, focusing on quality investments and adjusting shareholding ratios based on future developments [3] Regulatory Compliance - The company strictly adheres to information disclosure regulations during investor relations activities, ensuring no significant undisclosed information leaks occurred [4]

Financial Performance - The company's operating revenue for Q3 2024 was ¥148,498,997.57, a decrease of 23.11% compared to the same period last year[2] - The net profit attributable to shareholders was -¥46,325,582.44, representing a decline of 11,568.02% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥42,520,609.55, a decrease of 663.13% compared to the previous year[2] - Total operating revenue for Q3 2024 was ¥540,562,431.05, a decrease of 30.4% compared to ¥776,629,583.53 in the same period last year[12] - Net profit for Q3 2024 was a loss of ¥17,745,874.25, compared to a profit of ¥316,227,670.71 in Q3 2023[13] - The total profit margin for Q3 2024 was significantly impacted, resulting in a total profit of -¥37,166,807.13 compared to ¥344,637,149.36 in the previous year[12] - Basic and diluted earnings per share for Q3 2024 were both -¥0.0163, compared to ¥0.3091 in Q3 2023[13] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,911,633,438.27, down 5.83% from the end of the previous year[2] - The total assets decreased from CNY 6,277,761,845.44 at the beginning of the period to CNY 5,911,633,438.27 at the end of the period, representing a decline of approximately 5.83%[10] - Current assets decreased from CNY 2,639,981,026.24 to CNY 2,204,724,372.87, a reduction of about 16.53%[10] - Cash and cash equivalents decreased from CNY 683,831,097.67 to CNY 433,638,552.00, a decline of approximately 36.58%[10] - Accounts receivable decreased from CNY 200,470,744.96 to CNY 114,670,019.55, a drop of about 42.73%[10] - Inventory increased from CNY 144,456,874.27 to CNY 236,842,314.19, an increase of approximately 64.00%[10] - Total liabilities decreased from CNY 467,724,343.08 to CNY 273,444,310.16, a decline of about 41.52%[11] - The company's equity attributable to shareholders decreased from CNY 5,800,616,100.16 to CNY 5,629,778,019.03, a reduction of approximately 2.94%[11] - The company reported a significant decrease in accounts payable from CNY 213,161,758.49 to CNY 97,611,063.90, a decline of about 54.30%[11] - The company’s non-current assets increased from CNY 3,637,780,819.20 to CNY 3,706,909,065.40, an increase of approximately 1.90%[10] - The company’s retained earnings decreased from CNY 4,077,765,187.30 to CNY 3,906,927,106.17, a decline of about 4.18%[11] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥127,831,479.42, a decrease of 43.00% year-on-year[2] - Cash flow from operating activities was ¥127,831,479.42, down from ¥224,281,650.22 in the previous year[14] - The net cash flow from financing activities was -154,102,500.00, compared to -102,735,000.00 in the previous year, indicating a significant increase in cash outflow[15] - The cash and cash equivalents at the end of the period decreased to 423,550,721.97 from 572,786,732.95, reflecting a decline of approximately 26% year-over-year[15] - The net increase in cash and cash equivalents was -116,492,719.79, contrasting with a positive increase of 45,588,113.35 in the same period last year[15] - The company reported a significant increase in cash outflow for investment activities, totaling ¥419,921,793.54, up from ¥230,924,812.33[14] Expenses - The company's sales expenses decreased by 56% year-on-year, mainly due to an increase in products included in the centralized procurement scope[5] - The financial expenses increased by 48.27% year-on-year, primarily due to reduced interest income from interest rate cuts[5] - Research and development expenses were ¥98,929,930.35, slightly down from ¥101,199,404.42 year-over-year[12] - The company experienced a decrease in sales expenses, which were ¥91,222,553.23, down from ¥207,308,972.65 year-over-year[12] Shareholder Information - The company reported a total of 61,868 common shareholders at the end of the reporting period[6] - Major shareholder Xu Mingbo holds 22.62% of the shares, totaling 232,406,307 shares[6] Other Information - The report for the third quarter was not audited, which may affect the reliability of the financial data presented[15] - The company began implementing new accounting standards from 2024, which may influence future financial reporting and performance metrics[15] - The fair value changes of financial assets resulted in a loss of approximately ¥1.22 billion for the year-to-date, compared to a gain of ¥0.84 billion in the same period last year[5] - The impact of exchange rate changes on cash and cash equivalents was -3.45, compared to a positive impact of 1,870.64 in the previous year[15]

证券代码：002038 证券简称：双鹭药业 公告编号：2024-033 北京双鹭药业股份有限公司 关于高级管理人员减持计划期限届满暨实施结果的公告 公司董事、董事会秘书梁淑洁女士保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 北京双鹭药业股份有限公司（以下简称"公司"）于 2024 年 6 月 25 日披露了《北京双 鹭药业股份有限公司关于高级管理人员减持股份预披露公告》（公告编号：2024-024），公司 董事兼董事会秘书梁淑洁女士持有本公司 2,000,759 股（占本公司总股本比例 0.1947%），计 划在预披露公告之日起十五个交易日后的三个月内（即 2024 年 7 月 16 日至 2024 年 10 月 15 日，窗口期不减持），以集中竞价交易方式减持所持公司股份合计不超过 500,190 股（占 本公司总股本比例不超过 0.0487%）。 公司近日收到梁淑洁女士出具的《股份减持计划实施完成的告知函》，现将有关情况公 告如下： 一、股东减持情况 | 股东名称 | 减持方式 | | | 减持时间 ...

证券代码：002038 证券简称：双鹭药业 公告编号：2024-032 北京双鹭药业股份有限公司 关于获得依替巴肽注射液药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局 （ 以 下 简 称 " 国 家 药 监 局 " ） 核 准 签 发 的 依 替 巴 肽 注 射 液 （ 商 品 名 ： 依 文 ® ） （10ml:20mg）《药品注册证书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：依替巴肽注射液 剂 型：注射剂 规 格：10ml:20mg 注册分类：化学药品 3 类 生产企业：北京双鹭药业股份有限公司 该产品为国家医保目录乙类品种，2022 年 7 月入选第七批国家集中招标采购产品目 录。截止到目前该产品同规格通过一致性评价的企业已达八家，本次公司产品获批视同通 过一致性评价。 三、对上市公司的影响及风险提示 该药品的获批将丰富公司心脑血管治疗领域的产品储备，增加公司抗血小板聚集和抗 血栓药物的储备。与公司已经通过一致性评价的依诺肝素钠注射液（依理®） ...

Financial Performance - Revenue for the reporting period was RMB 392.06 million, a decrease of 32.81% compared to the same period last year[12] - Net profit attributable to shareholders of the listed company was RMB 29.59 million, a significant decrease of 90.67% year-on-year[12] - Net cash flow from operating activities was RMB 135.81 million, down 28.62% compared to the previous year[12] - Basic earnings per share (EPS) were RMB 0.03, a decrease of 90.32% compared to the same period last year[12] - Total assets at the end of the reporting period were RMB 6.09 billion, a decrease of 2.97% compared to the end of the previous year[12] - The weighted average return on equity (ROE) was 0.51%, down 5.13 percentage points from the same period last year[12] - Revenue for the reporting period was RMB 392.06 million, a decrease of 32.81% year-over-year[31] - Net profit attributable to shareholders was RMB 29.59 million, a significant decline of 90.67% year-over-year[31] - R&D investment totaled RMB 117.12 million, down 35.98% year-over-year, with R&D expenses at RMB 57.42 million, a decrease of 6.03%[31] - Sales revenue of key products such as Temozolomide and Recombinant Human Basic Fibroblast Growth Factor decreased by 24.61% and 27.45% respectively[31] - Revenue from the pharmaceutical industry accounted for 99.29% of total revenue, with a year-over-year decrease of 32.57%[33] - Revenue from biological and biochemical drugs was RMB 147.82 million, a decrease of 30.21% year-over-year[33] - Revenue from chemical drugs was RMB 239.04 million, a decrease of 33.75% year-over-year[33] - Revenue from the Northeast region decreased by 48.52% year-over-year, while revenue from the total distribution channel (non-regional and export business) increased by 235.10%[34] - Gross margin for the pharmaceutical industry was 77.05%, a decrease of 6.44% year-over-year[34] - The company's cash and cash equivalents increased by 182.63% year-over-year, primarily due to the absence of dividend distribution during the reporting period[32] - The company's monetary funds at the end of the reporting period amounted to 670,983,014.82 yuan, accounting for 11.02% of total assets, an increase of 0.13% compared to the previous year[35] - Accounts receivable decreased by 0.66% to 154,045,649.68 yuan, representing 2.53% of total assets[35] - Inventory increased by 0.62% to 178,060,203.85 yuan, accounting for 2.92% of total assets[35] - Long-term equity investments increased by 0.57% to 913,622,554.54 yuan, representing 15.00% of total assets[36] - The company's financial assets decreased by 118,495,945.17 yuan due to fair value changes, with a total financial asset value of 766,480,823.70 yuan at the end of the period[37] - The company's monetary funds of 15.78 million yuan were judicially frozen due to a contract dispute involving its partners[38] - The company invested 22,000,000.00 yuan during the reporting period, a 100.00% increase compared to the same period last year[39] - The company invested 40,000,000.00 yuan in Suzhou Pulekang Pharmaceutical Technology Co., Ltd., holding an 11.77% stake[40] - The company's investment in Fosun Pharma decreased to 28,213,002.00 yuan from an initial investment cost of 36,080,160.76 yuan[41] - The company's investment in Shouyao Holdings decreased to 277,864,421.14 yuan from an initial investment cost of 90,000,000.00 yuan[41] - The company's total assets as of June 30, 2024, amounted to 6,091,213,644.22 yuan, a decrease from 6,277,761,845.44 yuan at the beginning of the period[91] - The company's monetary funds decreased to 670,983,014.82 yuan from 683,831,097.67 yuan at the beginning of the period[91] - Accounts receivable decreased to 154,045,649.68 yuan from 200,470,744.96 yuan at the beginning of the period[91] - Inventory increased to 178,060,203.85 yuan from 144,456,874.27 yuan at the beginning of the period[91] - Long-term equity investments increased to 913,622,554.54 yuan from 905,919,506.61 yuan at the beginning of the period[92] - Total liabilities decreased from 467,724,343.08 yuan to 252,391,989.87 yuan, a significant reduction of 46%[93] - Total assets decreased from 6,131,717,222.05 yuan to 5,922,705,692.02 yuan, a reduction of 3.4%[95] - Current liabilities decreased from 391,826,154.69 yuan to 195,247,243.62 yuan, a reduction of 50.2%[96] - Non-current liabilities decreased from 94,398,070.79 yuan to 73,918,687.65 yuan, a reduction of 21.7%[93] - Total owner's equity decreased slightly from 5,810,037,502.36 yuan to 5,838,821,654.35 yuan, a reduction of 0.5%[93] - Cash and cash equivalents decreased from 649,744,930.38 yuan to 625,674,038.65 yuan, a reduction of 3.7%[94] - Trade receivables decreased from 199,604,359.53 yuan to 153,568,359.68 yuan, a reduction of 23.1%[95] - Inventory increased from 203,329,809.58 yuan to 222,869,256.51 yuan, an increase of 9.6%[95] - Development expenditure increased from 474,733,109.74 yuan to 510,682,796.54 yuan, an increase of 7.6%[95] - Long-term equity investments increased slightly from 1,157,401,580.12 yuan to 1,165,427,296.15 yuan, an increase of 0.7%[95] - Total operating revenue for the first half of 2024 was RMB 392.06 million, a decrease from RMB 583.51 million in the same period last year[98] - Net profit attributable to the parent company's shareholders was RMB 29.59 million, down significantly from RMB 317.16 million in the first half of 2023[99] - R&D expenses for the first half of 2024 were RMB 57.42 million, slightly lower than the RMB 61.10 million in the same period last year[98] - Sales expenses decreased to RMB 48.80 million in the first half of 2024, compared to RMB 141.16 million in the first half of 2023[98] - Basic earnings per share for the first half of 2024 were RMB 0.03, a significant drop from RMB 0.31 in the same period last year[99] - Total comprehensive income for the first half of 2024 was RMB 28.78 million, compared to RMB 316.18 million in the first half of 2023[99] - Operating profit for the first half of 2024 was RMB 18.48 million, a sharp decline from RMB 350.36 million in the same period last year[98] - The company's financial income was RMB 4.84 million in the first half of 2024, down from RMB 7.41 million in the same period last year[98] - Total assets impairment loss for the first half of 2024 was RMB 13.38 million, compared to RMB 28.04 million in the same period last year[98] - The company's investment income for the first half of 2024 was RMB 14.68 million, down from RMB 37.43 million in the same period last year[98] - Sales revenue from goods and services in H1 2024 decreased to 452.51 million yuan from 582.50 million yuan in H1 2023, a decline of 22.3%[103] - Net cash flow from operating activities in H1 2024 was 135.81 million yuan, down 28.6% compared to 190.25 million yuan in H1 2023[103] - Tax refunds received in H1 2024 increased significantly to 17.41 million yuan, up 167.8% from 6.50 million yuan in H1 2023[103] - Cash outflow for purchasing goods and services in H1 2024 rose to 190.36 million yuan, a 46.0% increase from 130.38 million yuan in H1 2023[103] - Net cash flow from investing activities in H1 2024 improved to -26.97 million yuan, compared to -49.01 million yuan in H1 2023[105] - Cash and cash equivalents at the end of H1 2024 increased to 648.88 million yuan, up 14.7% from 565.71 million yuan at the end of H1 2023[105] - Parent company's operating cash flow in H1 2024 was 101.72 million yuan, a 48.5% decrease from 197.55 million yuan in H1 2023[106] - Parent company's investment cash flow in H1 2024 improved to -4.11 million yuan, compared to -61.96 million yuan in H1 2023[107] - Total owner's equity at the end of H1 2024 stood at 5.81 billion yuan, with minority interests of 9.42 million yuan[108] - The company's comprehensive income for the period increased by RMB 29,590,001.31[109] - The total comprehensive income for the period attributable to the parent company's owners was RMB 317,164,126.27[111] - The company allocated RMB 102,735,000.00 for profit distribution to owners (or shareholders)[112] - The company's total owner's equity at the end of the period was RMB 5,692,682,541.11[113] - The company's capital reserve at the beginning of the period was RMB 43,846,655.86[111] - The company's undistributed profit at the end of the period was RMB 10,171,087.18[113] - The company's general risk reserve at the beginning of the period was RMB 3,763,808.24[111] - The company's total owner's equity at the beginning of the period was RMB 5,479,238,208.27[111] - The company's total comprehensive income for the period decreased by RMB 984,793.43 due to minority interests[111] - The company's total owner's equity at the end of the period increased by RMB 213,444,332.84 compared to the beginning of the period[111] - The company's total owner's equity at the end of the period was 5,679,253,677.35 yuan, an increase of 11,006,215.86 yuan compared to the beginning of the period[114][115] - The company's comprehensive income for the period was 11,006,215.86 yuan[114] - The company's undistributed profit at the end of the period was 3,953,643,608.31 yuan, an increase of 11,006,215.86 yuan compared to the beginning of the period[115] - The company's capital reserve at the end of the period was 49,185,236.14 yuan, unchanged from the beginning of the period[114][115] - The company's total owner's equity at the beginning of the period was 5,668,247,461.49 yuan[114] - The company's undistributed profit at the beginning of the period was 3,942,637,392.45 yuan[114] - The company's total owner's equity at the end of the previous year was 5,400,453,691.35 yuan[116] - The company's undistributed profit at the end of the previous year was 3,693,420,451.92 yuan[116] - The company's capital reserve at the end of the previous year was 43,416,236.13 yuan[116] - The company's total owner's equity at the beginning of the previous year was 5,400,453,691.35 yuan[116] Dividend Policy - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[2] Company Information - The company's registered address, office address, website, and email remained unchanged during the reporting period[9] - The company's stock code is 002038, and it is listed on the Shenzhen Stock Exchange[7] - The company's legal representative is Xu Mingbo[7] Accounting Standards - The company reported no differences in net profit and net assets between International Financial Reporting Standards (IFRS) and Chinese Accounting Standards (CAS) for the reporting period[13] Non-Recurring Gains and Losses - Non-recurring gains and losses for the period totaled a net loss of -90,921,265.42 yuan, with significant items including government subsidies of 5,307,446.48 yuan and losses from financial asset transactions of -118,495,945.17 yuan[14] Industry and Products - The company operates in the pharmaceutical manufacturing industry (C27) and focuses on gene engineering and related drug R&D and production[16] - Over 30 years, the company has developed 80+ products, including 3 Class 1 new drugs, and has received multiple national and municipal awards for scientific progress[17] - Core products include biological preparations for wound repair and oncology treatments, with key products like Lifegen (human granulocyte colony-stimulating factor) and Megal (interleukin-11) being major profit drivers[17] - The company has 8 major production bases across Beijing, Hebei, and Henan, producing various dosage forms including tablets, capsules, injections, and biological products[19] - Main product lines include 15 oncology and immunomodulatory drugs, 8 cardiovascular drugs, 13 anti-infective drugs, and 5 diabetes drugs[20] - The company's product "立生素 ® 重组人粒细胞刺激因子注射液" has been recognized as a National Key New Product and has won multiple awards including the Beijing Science and Technology Progress Second Prize[21] - "久立 ® 聚乙二醇化人粒细胞刺激因子注射液" is a long-acting formulation included in the National High-end Formulation Competitiveness Enhancement Project[21] - "迈格尔 ® 注射用人白介素 -11" is part of the National "863" Plan and has been granted a national invention patent[21] - "欣吉尔 ® 注射用人白介素 -2" is the only alanine-mutated interleukin-2 internationally and has been listed as a National Key New Product[21] - "交宁 ® 替莫唑胺胶囊" has passed consistency evaluation and won the Beijing Science and Technology Progress Third Prize[21] - "立生 ® 来那度胺胶囊" has received national major project funding and passed consistency evaluation[21] - "立生宁 ® 注射用三氧化二砷" is a National Essential Medicine and a Beijing Independent Innovation Product[21] - "欧宁 ® 注射用胸腺五肽" has a formulation patent and has been granted a national invention patent[21] - Xinerjin® Paclitaxel Injection has passed consistency evaluation and won bids in centralized procurement renewals, used for ovarian cancer, breast cancer, and non-small cell lung cancer[23] - Lixinwei® Voriconazole Tablets/Injection passed consistency evaluation and won bids in centralized procurement renewals, used for fungal infections in adults and children over 2 years old[23] - Xinfutai® Voglibose Tablets, a 2023 new product, passed consistency evaluation and won bids in centralized procurement renewals, used for improving postprandial hyperglycemia in diabetic patients[23] - Dapagliflozin Tablets, approved in 2023, passed consistency evaluation, used for adult patients with type 2 diabetes[23] - Lixin® Arginine Injection, a 2023 new product, passed consistency evaluation and won bids in centralized procurement renewals, used for improving neurological symptoms in acute ischemic stroke patients[23] - Lixin® Rivaroxaban Tablets passed consistency evaluation, used for preventing postoperative thrombosis, with small-dose formulations under application[23] - Lixin® Cyclosporine Injection/Soft Capsules, used for preventing rejection in organ and bone marrow transplants, has applied for consistency evaluation[23] - Xinfutai® Mycophenolate Mofetil Dispersible Tablets, used for preventing rejection in kidney, heart, or liver transplants, listed as a Beijing independent innovation product[23] - Beikene®/Xinbeike® Compound Coenzyme for Injection, used for acute and chronic hepatitis, is a national exclusive product and won the Beijing Science and Technology Award[23] - Yili® Enoxaparin Sodium Injection passed consistency evaluation, used for preventing venous thromboembolism, and won the Shandong Science and Technology Progress Award[23] Strategic Development - The company plans to increase the proportion of innovative drug development and services, leveraging its financial strength to invest in high-quality targets in the pharmaceutical and health sectors[25] - The company aims to expand its product portfolio to over 20 products within two years, focusing on common and seasonal diseases[26] - The company employs a "VIC model" (VC + IP + CRO) for innovative drug development to mitigate risks and accelerate the process[26] - The company has achieved breakthroughs in oral and injectable production capacity and quality, aiming to double current levels within two years[26] - The company's sales strategy includes a mix of direct sales and distribution, with a focus on expanding into grassroots medical institutions and private hospitals[26] - The company is actively exploring new sales channels, including e-commerce, to diversify its sales model and reduce reliance on a single channel[26] - The company has successfully launched several new products in 2023 and 2024, including Gabapentin Capsules, Pregabalin Oral

证券代码：002038 证券简称：双鹭药业 公告编号：2024-031 北京双鹭药业股份有限公司 第九届监事会第三次会议决议公告 三、备查文件 经与会监事签字的监事会决议。 特此公告。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 （一）审议通过了《关于 2024 年半年度报告及摘要的议案》 经审核，监事会认为董事会编制和审核北京双鹭药业股份有限公司《2024 年半年度报告》及 《2024 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《北京双鹭药业股份有限公司 2024 年半年度报告摘要》（2024-029）详见 2024 年 8 月 26 日 《中国证券报》、巨潮资讯网公司公告，《北京双鹭药业股份有限公司 2024 年半年度报告》详见 指定信息披露巨潮资讯网（www.cninfo.com.cn）。 议案表决情况：本议案有效表决票 3 票，同意 3 票，反对 0 票，弃权 0 票 一、监事会会议召开情况 北京双鹭药业股份有限公司（以下简称"公 ...

证券代码：002038 证券简称：双鹭药业 公告编号：2024-030 北京双鹭药业股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 会议以投票表决方式，审议通过了《关于 2024 年半年度报告及摘要的议案》 北京双鹭药业股份有限公司董事会 议案内容详见公司于 2024 年 8 月 26 日披露在《中国证券报》、巨潮资讯网的《北京双鹭药业 股份有限公司 2024 年半年度报告摘要》（公告编号：2024-029），以及披露在指定信息披露网站巨潮 资讯网（www.cninfo.com.cn）的《北京双鹭药业股份有限公司 2024 年半年度报告》。 二〇二四年八月二十六日 经与会董事签字并加盖公司公章的董事会决议。 特此公告。 该议案已经公司董事会审计委员会 2024 年第六次会议全体委员一致同意审议通过。 议案表决情况：本议案有效表决票 6 票，同意 6 票，反对 0 票，弃权 0 票。 三、备查文件 二、董事会会议审议情况 一、 董事会会议召开情况 北京双鹭药业股份有限公司（以下简称"公司"）第九届董事会第三次会议于 ...